ClinicalTrials.gg
Not yet recruitingNCT07017855STAR-4VTUpdated Jun 12, 2025

Stereotactic Radiosurgery as Second-line Therapy for Ventricular Tachycardia

An interventional study of Stereotactic Arrhythmia Radioablation (STAR) and Catheter Ablation in Ventricular Tachycardia, Monomorphic, Ventricular Tachycardia, Sustained and Ventricular Tachycardia (VT), sponsored by Medical University of Silesia. Not yet recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by Medical University of Silesia · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Tachycardia, Ventricular with a site in Poland — 5 open to participants now, 6 under way, none of them phase 3. Tachycardia, Ventricular · Poland.

Planned enrollment
12th of 15
150 · median 504
Started
2025
with 1 other
No phase
11 of 19
5 open now
Registered
17th of 19
by date
Lead sponsor
1 of 19
Medical University of Silesia

Among the 19 studies in Tachycardia, Ventricular with a site in Poland, this one is the 12th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2025, is one of 11 with no phase, and was the 17th registered.

Tachycardia, Ventricular

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

Browse Tachycardia, Ventricular studies →

Open to participants now

5 of the 19 studies in Tachycardia, Ventricular with a site in Poland are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Tachycardia, Ventricular with a site in Poland, or all of them as a file.
02

Study summary

The aim of the study is to compare the efficacy and safety of treating recurrent sustained Ventricular Tachycardia (sVT) after prior Catheter Ablation (CA) in patients with Implanted Cardioverter-Defibrillator (ICD) between re-do of conventional endocardial CA and Stereotactic Arrhythmia Radioablation (STAR).

Read the detailed description

Study Objectives:

To evaluate the safety and efficacy of Stereotactic Arrhythmia Radioablation (STAR) as a second-line therapy for sustained Ventricular Tachycardia (sVT) in optimally treated patients following endocardial Catheter Ablation (CA).

Study Design:

This study is a single-center randomized, noninferiority, head-to-head control trial comparing the efficacy and safety of two ablation methods for recurrent sVT after failing CA.

Patient Population:

Optimally treated patients aged ≥18 with Implantable Cardioverter-Defibrillators (ICD) in the primary or secondary prevention of sudden cardiac death (SCD), who have undergone endocardial CA and are candidates for re-ablation of recurrent symptomatic ventricular tachycardia (VT) following the 2022 European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of SCD.

The planned size of the group is 150.

The planned recruitment period is 42 months, and the observation period is 18 months.

Patients will be randomly assigned to experimental and control groups for a 1:1 group size ratio. The block randomized stratification method will be used with a central randomization system. Sex and left ventricular ejection fraction (≤40% vs. >40%) will be stratifying factors.

Intervention:

The intervention under investigation (experimental) will be STAR ablation. The standard intervention will be repeated endocardial radiofrequency CA. The target area for sVT ablation will be the arrhythmogenic substrate, defined by electrophysiological study (EPS) with three-dimensional electroanatomical mapping (obligatory in the standard therapy arm, optional in the STAR arm) and imaging tests (i.e., MSCT/CMR/PET-CT). The following will be integrated using dedicated computer software: 1) anatomical data-locating the arrhythmogenic scar area with channels of heterogeneous tissue-obtained using MSCT, CMR, PET-CT/SPECT, 2) three-dimensional electroanatomical maps-locating electrograms showing low peak-to-peak voltage, local abnormal ventricular activities, the sequence of myocardial activation, and critical isthmus sites for re-entrant VT, and 3) electrocardiograms detected during sinus rhythm and ventricular pacing during EPS. In the experimental arm, the obtained data will become the basis for STAR planning by a team consisting of a diagnostic cardiologist, radiologist, electrophysiologist, and radiotherapist. The obtained data will become the basis for endocardial CA planning in the control arm.

Observation:

Observation will include 1) clinical assessment-with the determination of the New York Heart Association functional class and exercise capacity in the 6-minute walk test (6MWT); 2) echocardiography-with the assessment of global and segmental left ventricular systolic function, mitral valve function, and the presence of fluid in the pleural and pericardial cavities; 3) parameters of pacing, sensing, lead impedance, and ventricular arrhythmic events recorded by the ICD/CRT-D; 4) QoL; and 5) procedure-related adverse events. Evaluation will be performed at 1, 3, 6, 12, and 18 months post-procedure, with endpoints assessed at 6 and 18 months.

The co-primary endpoints will assess 1) treatment efficacy, defined as the number of events of monomorphic sVT over six months following the comparison procedures, and 2) treatment safety, defined as no procedure-related serious adverse events.

The most important clinical parameters evaluating the effectiveness of ablation (i.e., post-procedural reduction in the sVT burden, occurrence/time to the first sVT episode, number of adequate ICD/CRT-D therapies, number of hospitalizations for arrhythmic reasons, QoL improvement) and mortality (death from any cause) were selected as secondary endpoints.

03

Conditions studied

  • Ventricular Tachycardia, Monomorphic
  • Ventricular Tachycardia, Sustained
  • Ventricular Tachycardia (VT)
  • Ventricular Tachycardia (V-Tach)
  • Stereotactic Body Radiation Therapy (SBRT)
  • Stereotactic Techniques
  • Stereotactic Radiation
  • Cardioverter-Defibrillators, Implantable

Keywords

  • Ventricular Tachycardia
  • VT
  • Stereotactic Arrhythmia Radioablation
  • STAR
  • Implanted Cardioverter-Defibrillator
  • ICD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years at the time of enrollment.
  2. Presence of structural heart disease (SHD) of either ischemic or non-ischemic etiology.
  3. Implanted ICD or CRT-D device for primary or secondary prevention of sudden cardiac death (SCD).
  4. History of at least one endocardial CA procedure targeting a substrate of monomorphic sVT.
  5. Recurrence of at least one and symptomatic episode of monomorphic sVT.
  6. Optimal pharmacological treatment of underlying SHD, including maximally tolerated doses of guideline-recommended heart failure therapies and appropriate antiarrhythmic management.
  7. Provision of written prior to study participation.

Exclusion criteria

Exclusion Criteria:

  1. Reversible cause of sVT recurrence, particularly acute coronary syndrome (ACS), acute myocarditis, or lead-related infective endocarditis (LDIE).
  2. Myocardial infarction (MI) or cardiac surgery within the last 40 days.
  3. Idiopathic sVT unrelated to SHD or sVT associated with genetically determined channelopathies.
  4. Ongoing or persistently recurrent hemodynamically unstable sVT until clinical stabilization is achieved.
  5. Acute decompensation of heart failure, classified as (NYHA) Class IV, until clinical stabilization is achieved.
  6. Worsening angina, classified as Canadian Cardiovascular Society (CCS) Class III or IV until coronary diagnostic evaluation and clinical stabilization are completed.
  7. A mobile thrombus within the left ventricle (LV).
  8. Presence of a left ventricular assist device (LVAD).
  9. Presence of comorbidities or known risk factors for CA complications that, in the judgment of the electrophysiologist, constitute a to the procedure for safety reasons.
  10. Active, uncontrolled and/or chemotherapy or immunotherapy administered or planned within 1 month of the scheduled ablation procedure.
  11. Features of an active systemic, pulmonary, or pericardial inflammatory process requiring systemic treatment (disease-modifying therapies, , ) within the past 6 months.
  12. Presence of comorbidities or known risk factors for radiotherapy complications that, in the judgment of the radiation oncologist, constitute a contraindication to STAR for safety reasons.
  13. Pregnancy or breastfeeding.
  14. Systemic disease that limits the probability of survival to less than 1 year
  15. Other comorbidities, addictions, or social indications that, in the investigator's opinion, would preclude practical cooperation or otherwise disqualify the patient from participation in the clinical study.
  16. Refusal to participate or lack of written for study participation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Stereotactic Arrhythmia Radioablation (STAR) procedure

    In the arm randomized to STAR (alternative experimental therapy), the procedure will involve the elimination of the sVT substrate using ionizing radiation at a dose of 25 Gy, employing highly conformal stereotactic techniques. The STAR procedure will be performed in a radiation oncology department according to a protocol developed by the research team, based on the American Association of Physicists in Medicine (AAPM) report on stereotactic radiotherapy, guidelines for radiotherapy in patients with cardiac implantable electronic devices (CIEDs), and the expert consensus on the implementation and use of STAR in treatment-resistant sVT.

    Radiation: Stereotactic Arrhythmia Radioablation (STAR)

  • Active comparator
    Active Comparator: Catheter Ablation using Radiofrequency Current

    In the arm randomized to CA (reference - standard therapy), the procedure will involve the elimination of the sVT substrate using energy transmitted from a generator through a catheter. The CA procedure will be performed in accordance with the expert consensus of the Heart Rhythm Society (HRS), European Heart Rhythm Association (EHRA), Asia Pacific Heart Rhythm Society (APHRS), and Latin American Heart Rhythm Society (LAHRS) on ventricular arrhythmia ablation.

    Procedure: Catheter Ablation

Interventions

  • RadiationStereotactic Arrhythmia Radioablation (STAR)

    Radiotherapy Implementation: During treatment on a TrueBeam™ linear accelerator (Varian Medical Systems, Palo Alto, CA, USA), a planned radiation dose of 25 Gy will be delivered to the defined planning target volume (PTV) using highly conformal stereotactic techniques. Image-guided radiotherapy (IGRT), respiratory gating, and Triggered Tracking will be utilized, targeting the previously delineated defibrillation lead of the implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D), with position verification every 15 degrees of gantry rotation. Patient positioning will be performed using kV-kV imaging, based on pre-determined fiducial markers on the ICD/CRT-D defibrillation lead, followed by verification using gated cone-beam computed tomography (CBCT). Continuous ECG monitoring will be conducted throughout the treatment, and the patient will remain under cardiologist supervision.

  • ProcedureCatheter Ablation

    CA will be conducted in an electrophysiology laboratory and will routinely follow diagnostic procedures, including an electrophysiological study (EPS) and three-dimensional electroanatomical mapping (3D-EAM). Once sufficient data on the nature and location of the arrhythmic substrate have been obtained from the three primary mapping modules-voltage, activation, and propagation-spatial 3D-EAM maps will be integrated with a 3D left ventricular reconstruction from multislice computed tomography (MSCT) or cardiac magnetic resonance (CMR). Subsequently, ablation will be performed by delivering energy to predefined target sites identified as the arrhythmia source to close the sVT isthmus or eliminate late potentials (LPs) and/or low-amplitude ventricular activities (LAVAs). Following CA, a repeat induction attempt of sVT using programmed ventricular pacing (VP) will be conducted to verify procedural efficacy.

06

What researchers measure

Primary outcomes

  1. The burden of ventricular arrhythmias, defined as the total number of sustained ventricular tachycardia (sVT) events recorded during the 6-month observation period.

    Each documented sustained ventricular tachycardia (sVT) event, captured via electrocardiogram (ECG) or intracardiac electrogram (EGM) from the CIED memory, will be subject to physician adjudication. Automatic classification of arrhythmia type, number of sVT episodes, and number of therapies performed by the CIED will be accepted only in cases where EGM recordings are unavailable, e.g., due to device memory overflow resulting from a high volume of episodes. sVT criteria: 1. Meets detection criteria in the active VT or VF zone programmed in the ICD/CRT-D and triggers an appropriate therapy; or 2. Meets detection criteria in the VT monitoring zone programmed in the ICD/CRT-D and lasts ≥ 30 seconds; or 3. Is misclassified by the ICD/CRT-D as a supraventricular tachycardia but is reclassified as sVT after physician review of the EGM; or 4. Is recorded on surface ECG with a duration of ≥ 30 seconds.

    Time frame: 6 months

  2. Absence of treatment-related serious adverse events (SAEs) during the 18-month follow-up period

    All adverse events (AEs) assessed by the investigator as having a probable causal relationship with either the experimental therapy or standard therapy will be classified as adverse events and recorded in the study protocol. Serious Adverse Events (SAEs) Each adverse medical event meeting any of the following criteria will be classified as a Serious Adverse Event (SAE): * Results in the death of the patient. * Is life-threatening to the patient. * Results in permanent or significant disability or requires intervention to prevent permanent damage to tissues or organs. * Requires re-hospitalization or leads to an extension of the hospitalization related to the procedure by more than 24 hours.

    Time frame: 18 months

Secondary outcomes

  1. Reduction in ventricular arrhythmia burden, measured as the percentage decrease in the mean monthly number of sustained ventricular tachycardia events during the 6-month follow-up after therapy initiation, compared to corresponding period pre-treatment

    Sustained ventricular arrhythmias will be counted as stated in the Primary Outcome Measures.

    Time frame: 6 months

  2. Occurrence of sVT during the 18-month follow-up period

    Sustained ventricular arrhythmias will be counted as stated in the Primary Outcome Measures.

    Time frame: 18 months

  3. Time to first occurrence of sVT during the 18-month follow-up period.

    Sustained ventricular arrhythmias will be counted as stated in the Primary Outcome Measures.

    Time frame: 18 months

  4. Number of appropriate ICD/CRT-D therapies delivered during the 18-month follow-up period.

    Appropriate therapy will be defined as: a. Therapy (ATP or shock) delivered by the ICD/CRT-D due to sVT and confirmed by physician adjudication (after excluding supraventricular arrhythmias and/or sensing abnormalities); or b. External electrical or pharmacological cardioversion following physician-confirmed documentation of sVT on ECG. Only one therapy will be counted per sVT episode. In cases where multiple therapies are delivered sequentially during a single episode, the final effective therapy leading to episode termination will be considered and counted.

    Time frame: 18 months

  5. Number of hospitalizations due to arrhythmic causes during the 18-month follow-up period.

    Number of hospitalizations due to arrhythmic causes during the 18-month follow-up period.

    Time frame: 18 months

  6. All-cause mortality during the 18-month follow-up period.

    All-cause mortality during the 18-month follow-up period.

    Time frame: 18 months

  7. Improvement in quality of life assessed using the Polish version of the World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaire during the 18-month follow-up period.

    Improvement in quality of life assessed using the Polish version of the World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaire during the 18-month follow-up period.

    Time frame: 18 months

07

Study locations

1 site
  • Department of Electrocardiology, Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University in Katowice
    Katowice, Upper-Silesia 40-635, Poland
    • Krzysztof S. Gołba, Professor · Contactkgolba@sum.edu.pl · +48 32 359 88 90
    • Danuta Łoboda, MD, PhD · Contactdloboda@sum.edu.pl · +48 32 359 88 93
    • Danuta Łoboda, MD, PhD · Principal investigator
08

References and documents

Publications

  • Miszczyk M, Sajdok M, Bednarek J, Latusek T, Wojakowski W, Tomasik B, Wita K, Jadczyk T, Kurzelowski R, Drzewiecka A, Cybulska M, Gardas R, Jarosinski G, Dolla L, Grzadziel A, Zub K, Bekman A, Kaminiow K, Kozub A, Golba KS, Blamek S. Stereotactic management of arrhythmia - radiosurgery in treatment of ventricular tachycardia (SMART-VT). Results of a prospective safety trial. Radiother Oncol. 2023 Nov;188:109857. doi: 10.1016/j.radonc.2023.109857. Epub 2023 Aug 18. PubMed 37597807 ↗
  • Miszczyk M, Jadczyk T, Golba K, Wojakowski W, Wita K, Bednarek J, Blamek S. Clinical Evidence behind Stereotactic Radiotherapy for the Treatment of Ventricular Tachycardia (STAR)-A Comprehensive Review. J Clin Med. 2021 Mar 17;10(6):1238. doi: 10.3390/jcm10061238. PubMed 33802802 ↗

Individual participant data

Plan to share: Undecided — Due to General Data Protection Regulation (GDPR) - EU regulation on personal data protection (Regulation (EU) 2016/679).

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for May 2027, 22 months later.

Of 86 non-industry interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 70. This study's planned 22 months is below that.

Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2025
First posted
Jun 12, 2025
StartEst.
Jul 1, 2025
Primary completionEst.
May 1, 2027
CompletionEst.
Nov 1, 2028
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07017855
Responsible party
Sponsor
First posted
Jun 12, 2025
Start date
Jul 1, 2025 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Jun 12, 2025

Study contacts

Krzysztof S. Gołba, Professor
Contact
kgolba@sum.edu.pl
+48 32 359 89 90
Danuta Łoboda, MD, PhD
Contact
dloboda@sum.edu.pl
+48 32 359 88 93
Krzysztof S. Gołba, Professor
study director · Department of Electrocardiology, Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University in Katowice, Ziolowa 45/47, Katowice 40-635, Poland
Danuta Łoboda, MD, PhD
principal investigator · Department of Electrocardiology, Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University in Katowice, Ziolowa 45/47, Katowice 40-635, Poland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion